ZURA
Zura Bio is a biotechnology company focused on developing novel medicines for serious immune system disorders, with a portfolio targeting autoimmune and inflammatory conditions. The company emphasizes dual-pathway biology to address unmet needs beyond single-pathway therapies, aiming to deliver differentiated treatments across its therapeutic areas. Led by biotechnology entrepreneurs and pharma veterans, Zura Bio is advancing tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a focus on efficacy, safety, and dosing convenience. The organization is headquartered in Henderson, Nevada, USA, and engages with investors and patients through its pipeline and research updates.
No recent news for this company.